HALOZYME WKN: A0DLHS ISIN: US40637H1095 Forum: Aktien Thema: Hauptdiskussion
123,64
USD
-0,96 % -1,19
22. Oktober 2026, 23:27 Uhr,
UTP Consolidated
Kostenlose Aktienchance per SMS
Ausgewählte Trading-Einschätzungen aufs Handy.
Kommentare 167
Shareholder1909,
04.11.2025 16:17 Uhr
1
"Citizens hebt Kursziel für Halozyme auf 92 Dollar an – starkes Lizenzwachstum als Treiber"
https://de.investing.com/news/analyst-ratings/citizens-hebt-kursziel-fur-halozyme-auf-92-dollar-an--starkes-lizenzwachstum-als-treiber-93CH-3215207
CK_one,
18.02.2026 21:42 Uhr
0
https://m.de.investing.com/news/earnings/uberraschender-quartalsverlust-druckt-halozymeaktie-um-4--93CH-3348470?ampMode=1
Shareholder1909,
04.11.2025 16:17 Uhr
0
"Halozyme Q3 2025: Lizenzeinnahmen steigen um 52 %, Prognose nach starkem Wachstum erhöht"
https://de.investing.com/news/company-news/halozyme-q3-2025-lizenzeinnahmen-steigen-um-52--prognose-nach-starkem-wachstum-erhoht-93CH-3214378
Shareholder1909,
05.08.2025 23:42 Uhr
0
"Halozyme überzeugt mit Quartalsergebnis und erhöht Jahresprognose"
https://de.investing.com/news/earnings/halozyme-uberzeugt-mit-quartalsergebnis-und-erhoht-jahresprognose-93CH-3098490
Blacksheep,
05.08.2025 22:26 Uhr
1
Liest sich auch gut in der Kurzform😎
Halozyme Therapeutics press release (NASDAQ:HALO): Q2 Non-GAAP EPS of $1.54 beats by $0.31.
Revenue of $325.7M (+40.8% Y/Y) beats by $39.78M.
https://seekingalpha.com/news/4479053-halozyme-therapeutics-non-gaap-eps-of-1_54-beats-by-0_31-revenue-of-325_7m-beats-by-39_78m
Shareholder1909,
05.08.2025 22:17 Uhr
0
Additionally, the GAAP Diluted EPS saw an 85% increase year-over-year to $1.33, while Non-GAAP Diluted EPS increased by 69% year-over-year to $1.54. The company also raised its full-year 2025 financial guidance, projecting total revenue to be in the range of $1,275 to $1,355 million, reflecting a year-over-year growth of 26% to 33%. Adjusted EBITDA guidance was also increased to a range of $865 to $915 million, indicating a growth of 37% to 45% year-over-year. Non-GAAP Diluted EPS is now anticipated to be between $6.00 and $6.40, representing a growth of 42% to 51% year-over-year.
Shareholder1909,
05.08.2025 22:15 Uhr
0
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.54 per share which beat the analyst consensus estimate of $1.23 by 25.2 percent. This is a 69.23 percent increase over earnings of $0.91 per share from the same period last year. The company reported quarterly sales of $325.719 million which beat the analyst consensus estimate of $281.588 million by 15.67 percent. This is a 40.79 percent increase over sales of $231.353 million the same period last year.
Ben_M,
13.05.2025 18:02 Uhr
0
Halozyme hat erst vor wenigen Wochen die Guidance erneut angehoben ...
Ben_M,
13.05.2025 17:37 Uhr
0
Downgrade von Halozyme und J&J durch Leerink Partners aufgrund von Unsicherheiten hinsichtlich des Centers for Medicare & Medicaid Services und möglichen Preisdeckeln
Anakin,
07.05.2025 16:07 Uhr
0
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.111 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%, and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% - 35%1 https://www.prnewswire.com/news-releases/halozyme-raises-2025-financial-guidance-ranges-and-reports-strong-first-quarter-2025-results-302447541.html
Starke zahlen 💪
Blacksheep,
07.05.2025 6:28 Uhr
0
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
Announcing New $250M Share Repurchase
Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million
Net Income Increased 54% YOY to $118 million; GAAP Diluted EPS Increased 55% YOY to $0.93;
non-GAAP Diluted EPS Increased 41% YOY to $1.111
Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%,
and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% - 35%1
https://www.prnewswire.com/news-releases/halozyme-raises-2025-financial-guidance-ranges-and-reports-strong-first-quarter-2025-results-302447541.html
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | für alle, die es ehrlich meinen beim Traden. | ||
| 2 | SpaceX-Haupt-Hauptforum | -8,39 % | |
| 3 | Siemens Energy | -7,84 % | |
| 4 | ...Bloom-Energy... | -13,81 % | |
| 5 | DEUTZ Hauptdiskussion | -5,19 % | |
| 6 | VONOVIA Hauptdiskussion | -0,36 % | |
| 7 | Palantir ohne Schnickschnack | -2,46 % | |
| 8 | NVIDIA Hauptdiskussion | -4,07 % | |
| 9 | BioNTech Hauptdiskussion | -0,87 % | |
| 10 | NOKIA Hauptdiskussion | -13,67 % | Alle Diskussionen |
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | SpaceX-Haupt-Hauptforum | -8,39 % | |
| 2 | Siemens Energy | -7,84 % | |
| 3 | ...Bloom-Energy... | -13,81 % | |
| 4 | DEUTZ Hauptdiskussion | -5,19 % | |
| 5 | VONOVIA Hauptdiskussion | -0,36 % | |
| 6 | Palantir ohne Schnickschnack | -2,46 % | |
| 7 | NVIDIA Hauptdiskussion | -4,07 % | |
| 8 | BioNTech Hauptdiskussion | -0,87 % | |
| 9 | NOKIA Hauptdiskussion | -13,67 % | |
| 10 | BLOOM ENERGY A Hauptdiskussion | -13,81 % | Alle Diskussionen |